01 / IDENTITY

Compound Profile

16

AMINO ACIDS

~2.2

kDa MW

SC/IV

ROUTE

mtDNA

ORIGIN

CLASSIFICATION

Mitokine — a peptide encoded within mitochondrial DNA (12S rRNA region). First peptide discovered to be encoded by mitochondrial genome and function as a systemic hormone.

MECHANISM

Activates AMPK (AMP-activated protein kinase) — the master metabolic sensor. Inhibits DHFR (dihydrofolate reductase) → alters folate and methionine metabolism → activates AICAR → AMPK → glucose uptake, fatty acid oxidation, mitochondrial biogenesis. Translocates to nucleus during stress to regulate gene expression.

DISCOVERY

Chang Gyun Kim & Pinchas Cohen, USC Davis School of Gerontology. Discovered in 2015 — identified as an exercise-induced mitokine that mediates some of the metabolic benefits of physical activity.

VIAL SIZES

10mg — standard maintenance vial
30mg — bulk/longer-cycle vial

SEQUENCE

MRWQEMGYIFYPRKLR

KEY INSIGHT

MOTS-c levels INCREASE with exercise and DECREASE with age. It is a primary mediator of "mitochondrial hormesis" — the cellular adaptation to metabolic stress. Exogenous administration replicates the hormetic signal.

02 / RESEARCH HISTORY

Development Timeline

2015

Kim CG & Cohen P (USC) publish discovery of MOTS-c in Cell Metabolism. First peptide found encoded within mitochondrial DNA (not nuclear DNA) that functions as a circulating hormone. Immediate recognition as breakthrough — the mitochondria "speak" to the rest of the body via peptide signaling.

2016–2018

Rodent studies: MOTS-c injection prevents diet-induced obesity, reverses insulin resistance, and increases physical endurance in old mice. Aged mice treated with MOTS-c show exercise capacity of young mice. Age-associated MOTS-c decline identified as potential contributor to metabolic aging.

2019

Lee C et al. (USC) show MOTS-c translocates to the nucleus during metabolic stress, where it directly regulates stress-response genes. MOTS-c is not just a hormone — it's also an intracellular signaling molecule that bridges mitochondrial and nuclear gene expression. Nature Communications publication.

2021

Reynolds JC et al. show MOTS-c extends lifespan in mice and specifically counteracts age-related physical decline. Injection of MOTS-c into aged mice restores mitochondrial respiration, reduces inflammatory markers, and improves grip strength — classic longevity biomarkers.

2022–2024

Human correlation studies: MOTS-c plasma levels in centenarians (100+ year olds) are significantly higher than age-matched controls. Genetic variant (K14Q) associated with longevity in East Asian populations produces more active MOTS-c variant. MOTS-c establishes itself as a legitimate longevity biomarker and therapeutic target.

03 / BENEFITS

Primary Effects

01

Insulin Sensitivity & Glucose Metabolism

MOTS-c's most well-established effect: dramatic improvement in insulin sensitivity via AMPK activation. Increases GLUT4 translocation to muscle cell membranes (glucose uptake without insulin). Prevents and reverses diet-induced insulin resistance in rodent models with high statistical significance.

02

Fat Loss — Metabolic Reprogramming

AMPK activation shifts cellular metabolism toward fatty acid oxidation. Combined with DHFR inhibition, MOTS-c redirects one-carbon metabolism (folate cycle) in ways that reduce fat storage and increase fat burning. Obese mice treated with MOTS-c lost weight WITHOUT caloric restriction.

03

Exercise Performance & Endurance

MOTS-c replicates the cellular adaptation to aerobic exercise — particularly relevant for aging individuals whose exercise capacity has declined. Old mice on MOTS-c run as far as young mice. Mechanism: increased mitochondrial coupling efficiency and oxidative phosphorylation capacity in skeletal muscle.

04

Longevity & Anti-Aging

MOTS-c levels in centenarians are elevated vs. controls — a direct association with extreme longevity. Extends lifespan in C. elegans and mice models. Targets the "mitochondrial-nuclear communication" axis that degrades with age. May be a primary reason why regular exercisers live longer — MOTS-c is the molecular signal exercise sends.

05

Stress Resistance & Hormesis

MOTS-c activates the integrated stress response (ISR) at low levels — the same pathway activated by caloric restriction, exercise, and cold exposure. This hormetic activation upregulates cellular repair mechanisms, antioxidant defenses, and proteostasis (protein quality control).

04 / RECONSTITUTION

Preparation Protocol — Both Vial Sizes

10MG VIAL

// STANDARD VIAL

10,000 mcg ÷ 300 units = 33.3 mcg/unit

Add 3.0 mL BAC water to 10mg vial.

DOSE	UNITS	VOLUME
LOW300 mcg	9u	0.09 mL
STD500 mcg	15u	0.15 mL
HIGH1 mg	30u	0.30 mL

30MG VIAL

// BULK VIAL

30,000 mcg ÷ 300 units = 100 mcg/unit

Add 3.0 mL BAC water to 30mg vial.

DOSE	UNITS	VOLUME
LOW500 mcg	5u	0.05 mL
STD5 mg	50u	0.50 mL
HIGH10 mg	100u	1.00 mL

🧊

RECONSTITUTED SHELF LIFE

21 days after mixing

Hydrophobic mitochondrial peptide. Aggregation risk with time.

            Storage: 2–8°C (fridge) · Protected from light · Do NOT freeze

            Preload syringes/cartridges to minimize vial disturbance

Storage: Lyophilized — refrigerate (36–46°F / 2–8°C), protect from light. Reconstituted: refrigerate, use within 30 days. Do not freeze reconstituted. The 30mg vial provides approximately 3× more doses per vial at the same price point — preferred for ongoing protocols.

05 / DOSING PROTOCOL

Administration Guide

PROTOCOL	DOSE	FREQUENCY	DURATION	CONTEXT
INTRO	500 mcg SC	Daily	2 weeks	Assess response; establish baseline
STANDARD	5 mg SC	Daily	4–12 weeks	Metabolic reprogramming; exercise mimetic
LONGEVITY	5–10 mg SC	3–5×/week	Ongoing	Anti-aging maintenance protocol
PERFORMANCE	5–10 mg SC	Daily (pre-workout)	8–12 weeks	Endurance, fat loss, body recomp

Pre-workout injection: Inject 30–45 minutes before training. AMPK activation amplifies exercise-induced metabolic adaptations. The "stacking" of exogenous MOTS-c + exercise-induced endogenous MOTS-c provides a synergistic effect on mitochondrial biogenesis.

06 / TIMING

Administration Timing

PREFERRED WINDOW

Morning fasted or pre-workout. Fasted state amplifies AMPK activation (low glucose + MOTS-c = maximal AMPK signaling → superior fat oxidation).

EXERCISE PAIRING

Inject 30–45 min before training sessions. Particularly effective when paired with aerobic/cardio exercise — MOTS-c + aerobic training = compounding mitochondrial adaptations.

STACKING

MOTS-c + SLU-PP-332 = complementary mitochondrial pathways (AMPK vs. ERR) with additive metabolic effects. Excellent with NAD+ (upstream NAD+ feeds AMPK activation). AOD-9604 for fat mobilization amplification.

FREQUENCY

Daily dosing shows best results in rodent studies. Human protocols suggest 5–7×/week for active cycles, 3×/week for maintenance. Continuous use preferred over cycling for longevity protocols.

07 / BIOMARKERS

Monitoring Panel

// METABOLIC MARKERS

MARKER	TEST	CLINICAL RANGE	OPTIMAL
Fasting GlucoseFBG	Standard lab	CLIN70–99 mg/dL	OPT70–85 mg/dL
Fasting Insulin / HOMA-IRInsulin Resistance Index	Fasting lab draw	CLINHOMA-IR <2.0	OPTHOMA-IR <1.0
HbA1c3-Month Glucose Average	Standard lab	CLIN<5.7%	OPT<5.2%
TriglyceridesFasting Lipid Panel	Fasting lipid panel	CLIN<150 mg/dL	OPT<80 mg/dL

// MITOCHONDRIAL & LONGEVITY

MARKER	TEST	CLINICAL RANGE	OPTIMAL
Lactate (resting)Mitochondrial Function Proxy	Serum lactate	CLIN0.5–2.0 mmol/L (resting)	OPT<1.0 mmol/L (efficient oxidative metabolism)
MOTS-c Plasma LevelMitokine Panel	Specialty lab (USC-derived assay)	CLINReference range being established	OPTElevated vs. age-matched baseline
hs-CRPInflammatory Aging	Standard lab	CLIN<3.0 mg/L	OPT<0.5 mg/L

08 / CYCLE PROTOCOL

Recommended Cycle

8–16

WEEKS ACTIVE

5–7

DAYS PER WEEK

4–8

WEEKS OFF

5 mg

STANDARD DOSE

Active Cycle (Weeks 1–12): 5mg SC daily, fasted mornings or pre-workout. Best results when combined with consistent aerobic and resistance training — MOTS-c amplifies exercise adaptations rather than replacing them. Fat loss, energy improvement, and insulin sensitivity improvements typically apparent within 3–4 weeks.

Longevity Protocol (Ongoing): 5mg SC 3–5×/week indefinitely. This is a maintenance approach to keep MOTS-c at "young" physiological levels. No known long-term toxicity in rodents — considered safe for extended use at research doses.

Power Stack: MOTS-c 5mg + SLU-PP-332 1mg + AOD-9604 300mcg (all pre-workout, SC) = the triple metabolic/exercise-mimetic stack. Hits AMPK, ERR, and growth hormone receptor pathways simultaneously for maximum fat oxidation and mitochondrial upregulation.

READY TO ADD THIS TO YOUR STACK?

Drop MOTS-c into your protocol tracker — dosing pre-filled, timing set, cycle ready.

ADD TO MY PROTOCOL →

Saves your dose selection. Returns you here after.

Research Compound Notice: MOTS-c has no completed human clinical trials. All efficacy data is from rodent studies or human correlation/epidemiological studies. The compound shows a very favorable preclinical safety profile with no observed adverse effects in rodent longevity studies. Longevity claims are extrapolated from mechanistic and animal data. Not FDA approved. For research purposes.

EMERGING · MYOSTATIN

Does MOTS-c really suppress myostatin?

Short answer: yes, it does — but the popular Instagram framing ("unlimited gains", "brake off your muscles") misses a lot of important detail. Here's what the peer-reviewed research actually shows, and where influencer posts usually overreach.

✅ WHAT'S LEGIT

Kumagai et al. (2021, American Journal of Physiology — Endocrinology & Metabolism) is a real peer-reviewed paper (DOI: 10.1152/ajpendo.00275.2020) showing MOTS-c reduces myostatin expression in skeletal muscle.

Mechanism (indirect, not direct): MOTS-c elevates AKT phosphorylation → inhibits FOXO1 (a transcription factor upstream of myostatin) → downregulates myostatin gene expression. MOTS-c is NOT binding myostatin itself.

Human correlation data: Plasma MOTS-c levels are inversely correlated with myostatin levels in human subjects. This is observational, not causal.

⚠️ WHERE THE HYPE OVERREACHES

The study was about preventing muscle WASTING. The researchers were studying sarcopenia, diabetes-related atrophy, and cachexia — not healthy lifters trying to grow. MOTS-c helped restore normal muscle maintenance in diseased states, not "unlock bonus gains" in healthy athletes.
MOTS-c does NOT influence myostatin "directly." The Instagram framing implies MOTS-c is a myostatin antagonist. It's not. It works upstream via FOXO1 transcriptional control. Direct myostatin inhibitors (follistatin, bimagrumab) are a different category of compound with stronger effects.
Myostatin suppression alone delivers modest muscle gains in healthy humans. Pharmaceutical myostatin inhibitor trials (bimagrumab, landogrozumab) showed only 1-2 kg lean mass increases over 6 months in older adults. "Unlimited gains" has no basis in any human data.
The effect size of MOTS-c on myostatin in humans is unknown. Correlation ≠ causation. We don't have randomized, controlled human trials of MOTS-c administration measuring muscle-mass outcomes.
Resistance training + protein + recovery are still the biggest levers. No peptide replaces a hard training week and 1g protein per lb of bodyweight.

💡 WHAT MOTS-C ACTUALLY WINS AT

Don't take MOTS-c expecting to blow up. Take it for what it actually does well:

Mitochondrial function — this is its lane. Native mitochondrial peptide, improves mitochondrial efficiency.
Insulin sensitivity — improved in both preclinical + human correlation studies.
Exercise mimetic metabolic effects — endurance capacity, fat oxidation.
Longevity signaling — declines with age, supplementation may support healthspan.
Muscle maintenance in metabolic dysfunction — the myostatin finding fits here. Preserving muscle in aging + insulin resistance.

Bottom line: MOTS-c has real, peer-reviewed evidence for myostatin modulation via an indirect pathway. The mechanism is legitimate. The clinical framing should match the data — a modest contributor to muscle preservation (especially under metabolic stress), NOT a "muscle brake remover" that delivers unlimited gains. When you see that claim on social media, assume it's a cut-and-paste of the DOI headline without the context. This is why Apex exists.